BIIB022

· Biogen

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BIIB022, covering 2013-09-16 to 2017-01-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors [Phase 1]